TRADE NEWS: Agilent Technologies and Applied Proteomics Will Collaborate to Maximize Capabilities of Highly Multiplexed Protein Assays
Agilent
Technologies Inc. (NYSE:A) and Applied
Proteomics Inc. today agreed to collaborate on highly multiplexed
protein assays and workflow solutions for multiple reaction monitoring
through mass spectrometry. Proteins perform many important cellular
functions, are the targets of most drugs and therapies, and are often
used as biomarkers for detecting and monitoring disease.
Applied Proteomics will leverage Agilent 6490 Triple Quadrupole MS/MS,
1290 Infinity LC, RapidFire 360 MS system and Bravo liquid-handling
technologies to optimize the throughput of highly multiplexed proteomic
assays. Multiple reaction monitoring, a highly specific and sensitive
mass-spectrometry technique, can detect and quantify analytes from
plasma, serum and other biological samples. A multiplex assay can
simultaneously measure multiple analytes, such as proteins, peptides,
metabolites and lipids.
“The ability to quickly and accurately measure, monitor and analyze a
large number of protein biomarkers in a single test has important
applications for understanding human diseases and developing new
clinical diagnostics,” said John E. Blume, Ph.D., chief science officer
of Applied Proteomics. “Agilent’s innovation in mass spectrometry is an
important part of this collaboration as we work together to expand the
capabilities of multiplex protein assays.”
Applied Proteomics specializes in a proteomics platform solution with
mass spectrometry-based systems control and computational expertise to
rapidly collect, process and analyze proteins. Proteomics is the study
of the structure and function of proteins and how they interact within a
complex biological system.
“We are thrilled to be collaborating with Applied Proteomics, an
organization that has leading expertise in developing mass
spectrometry-based methods and instrumentation technologies for protein
quantification and proteome applications,” said Can Ozbal, director of
Agilent’s RapidFire business. “Agilent’s innovative automation,
measurement and software platforms transform complete workflow solutions
from sample preparation through data acquisition, analysis and
evaluation in quantitative proteomics and biomarker validation.”
About Applied Proteomics Inc.
Applied Proteomics Inc. is advancing the application of proteomics to
the development of diagnostics, companion diagnostics, and personalized
medicine applications to power better medical decisions and care. API
has developed a proteomics platform solution to make protein-based
biomarker discovery possible as a replicable, industrial application
ready to be applied to health diagnostic problems. API’s platform
combines improved instrumentation, faster computing and extensive genome
annotations with regimented standard operating procedures, extensive
quality controls, and documented processes spanning hundreds of steps
from sample collection to processing through informatics. API is
currently advancing several internal diagnostic development programs.
API is headquartered in San Diego, Calif. For more information, visit www.appliedproteomics.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company’s 20,500
employees serve customers in more than 100 countries. Agilent had
revenues of $6.9 billion in fiscal 2012. Information about Agilent is
available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130307005234r1&sid=ntxv4&distro=nx)